Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day
New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of Presbyopia First update on recruitment in APX3330 ZETA-1 Phase 2b trial: ~70% patients... | January 31, 2022